Promoting Patient Adherence to Iron Chelation Therapy: Findings from EPASS (EXJADE Patient Assistance and Support Services)

2.50
Hdl Handle:
http://hdl.handle.net/10755/164753
Category:
Abstract
Type:
Presentation
Title:
Promoting Patient Adherence to Iron Chelation Therapy: Findings from EPASS (EXJADE Patient Assistance and Support Services)
Author(s):
Latsko, Joan; Martens, Anne
Author Details:
Joan Latsko, Joan, MSN, CRNP, OCN, AOCNP, Nurse Practitioner, Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, USA, email: jmlatsko@wpahs.org; Anne Martens, RN, BioScript, Morris Plains, New Jersey
Abstract:
Clinical/Evidence Based Practice: Iron chelation therapy (ICT) is essential for treating chronic iron overload due to blood transfusions. Conventional ICT is burdensome, potentially leading to poor compliance. Deferasirox (Exjade) is an orally administered iron chelator that is less burdensome for patients, consequently improving compliance. Exjade is distributed through a group of specialty pharmacies that are a part of EPASS (EXJADE Patient Assistance and Support Services). In 2008, a nurse-support component was implemented that is delivered by nurses in specialty pharmacies, providing patients with high levels of nurse interaction. The purpose was to determine whether nurse support can improve patient adherence (percentage of patients receiving drug) to deferasirox. Through regular, strategically timed phone conversations, the nursing staff educated patients on iron overload and the importance of adherence to deferasirox. The service was offered to all patients starting therapy after 2008. Patients were able to contact the nursing staff as needed. Prescription data from January 2006 to October 2008 were used to assess adherence. Patient adherence was highest among patients who started deferasirox just after FDA approval (n=4254, JanuaryûJune 2006): 3-month, 6-month and 12-month adherence was 66%, 54% and 44%, respectively. With subsequent patient starts, adherence declined. Patients who started deferasirox in the second half of 2007 (n=1519) had 3-month, 6-month and 12-month adherence rates that were reduced by 7% (59% vs 66%), 12% (42% vs 54%) and 13% (31% vs 44%) compared to patients who started in the first half of 2006. Following the implementation of the nurse support program in 2008, 3-month and 6-month adherence rates for those patients starting deferasirox in January-June 2008 (n=1940) were higher compared with those patients starting treatment in July-December 2007 (3-month rate: 62% vs 59%; 6-month rate: 46% vs 42%). These results show that adherence rates for deferasirox were initially high due to patients switching from the more cumbersome treatment option. However adherence declined between 2006 and 2007 perhaps due to patients having no prior experience of ICT and being less likely to be compliant. The nurse support program increased adherence, confirming the important influence of nurses on patient outcome.
Repository Posting Date:
27-Oct-2011
Date of Publication:
27-Oct-2011
Conference Date:
2009
Conference Name:
34th Annual Oncology Nursing Society Congress
Conference Host:
Oncology Nursing Society
Conference Location:
San Antonio, Texas, USA
Note:
This is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.

Full metadata record

DC FieldValue Language
dc.type.categoryAbstracten_US
dc.typePresentationen_GB
dc.titlePromoting Patient Adherence to Iron Chelation Therapy: Findings from EPASS (EXJADE Patient Assistance and Support Services)en_GB
dc.contributor.authorLatsko, Joanen_US
dc.contributor.authorMartens, Anneen_US
dc.author.detailsJoan Latsko, Joan, MSN, CRNP, OCN, AOCNP, Nurse Practitioner, Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, USA, email: jmlatsko@wpahs.org; Anne Martens, RN, BioScript, Morris Plains, New Jerseyen_US
dc.identifier.urihttp://hdl.handle.net/10755/164753-
dc.description.abstractClinical/Evidence Based Practice: Iron chelation therapy (ICT) is essential for treating chronic iron overload due to blood transfusions. Conventional ICT is burdensome, potentially leading to poor compliance. Deferasirox (Exjade) is an orally administered iron chelator that is less burdensome for patients, consequently improving compliance. Exjade is distributed through a group of specialty pharmacies that are a part of EPASS (EXJADE Patient Assistance and Support Services). In 2008, a nurse-support component was implemented that is delivered by nurses in specialty pharmacies, providing patients with high levels of nurse interaction. The purpose was to determine whether nurse support can improve patient adherence (percentage of patients receiving drug) to deferasirox. Through regular, strategically timed phone conversations, the nursing staff educated patients on iron overload and the importance of adherence to deferasirox. The service was offered to all patients starting therapy after 2008. Patients were able to contact the nursing staff as needed. Prescription data from January 2006 to October 2008 were used to assess adherence. Patient adherence was highest among patients who started deferasirox just after FDA approval (n=4254, JanuaryûJune 2006): 3-month, 6-month and 12-month adherence was 66%, 54% and 44%, respectively. With subsequent patient starts, adherence declined. Patients who started deferasirox in the second half of 2007 (n=1519) had 3-month, 6-month and 12-month adherence rates that were reduced by 7% (59% vs 66%), 12% (42% vs 54%) and 13% (31% vs 44%) compared to patients who started in the first half of 2006. Following the implementation of the nurse support program in 2008, 3-month and 6-month adherence rates for those patients starting deferasirox in January-June 2008 (n=1940) were higher compared with those patients starting treatment in July-December 2007 (3-month rate: 62% vs 59%; 6-month rate: 46% vs 42%). These results show that adherence rates for deferasirox were initially high due to patients switching from the more cumbersome treatment option. However adherence declined between 2006 and 2007 perhaps due to patients having no prior experience of ICT and being less likely to be compliant. The nurse support program increased adherence, confirming the important influence of nurses on patient outcome.en_GB
dc.date.available2011-10-27T12:06:21Z-
dc.date.issued2011-10-27en_GB
dc.date.accessioned2011-10-27T12:06:21Z-
dc.conference.date2009en_US
dc.conference.name34th Annual Oncology Nursing Society Congressen_US
dc.conference.hostOncology Nursing Societyen_US
dc.conference.locationSan Antonio, Texas, USAen_US
dc.description.noteThis is an abstract-only submission. If the author has submitted a full-text item based on this abstract, you may find it by browsing the Virginia Henderson Global Nursing e-Repository by author. If author contact information is available in this abstract, please feel free to contact him or her with your queries regarding this submission. Alternatively, please contact the conference host, journal, or publisher (according to the circumstance) for further details regarding this item. If a citation is listed in this record, the item has been published and is available via open-access avenues or a journal/database subscription. Contact your library for assistance in obtaining the as-published article.-
All Items in this repository are protected by copyright, with all rights reserved, unless otherwise indicated.